文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

世界卫生组织非洲区域乙型肝炎病毒垂直传播:系统综述与Meta分析

Vertical transmission of hepatitis B virus in the WHO African region: a systematic review and meta-analysis.
PubMed 文献 · Lancet Glob Health · 2025-01-01

该系统综述与Meta分析检索1992年1月1日至2024年1月7日多个数据库,纳入113项孕妇HBsAg患病率研究和11项垂直传播研究。WHO非洲区域孕妇HBsAg患病率为6.2%(95%CI 5.3-7.2);2022年估计发生172000例垂直传播事件,较2001年峰值339000例下降。提高出生剂量疫苗接种覆盖率至90%并加用母体抗病毒预防可大幅减少传播并达到消除目标。

要点

  • WHO非洲区域孕妇HBsAg患病率为6.2%(95%CI 5.3-7.2)。
  • 2022年估计172000例垂直传播事件,较2001年峰值339000例下降。
  • 出生剂量疫苗覆盖率提至90%并加母体抗病毒预防可减少传播并达消除目标。

核心结论

  • 垂直传播是WHO非洲区域HBV传播的重要贡献因素,亟需扩大乙肝出生剂量疫苗接种和抗病毒预防,以实现垂直传播的消除。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Scopus、Africa Index Medicus和Africa Journals Online,时间范围为1992年1月1日至2024年1月7日,无语言限制。
  • 纳入113项报告孕妇HBsAg患病率的研究(190983名孕妇)和11项报告垂直传播的研究。
  • 采用二项混合模型(logit链接)估计HBsAg患病率和垂直传播(6-12月龄儿童HBsAg阳性),按婴儿疫苗接种状态分层。
  • 按各次区域估计活产数加权估计非洲次区域和WHO非洲区域的HBsAg患病率;利用WHO和UNICEF疫苗覆盖数据及UN人口估计估算传播事件。

主要发现

  • 未观察到偏倚风险与HBsAg患病率之间的关系。
  • 2022年估计发生172000例垂直传播事件(95%CI 82000-383000),占活产的0.4%,较2001年峰值339000例(95%CI 149000-634000;占全部活产的1.2%)下降。
  • 将出生剂量疫苗接种覆盖率提高至WHO目标90%可使垂直传播减少43.7%(95%CI 11.6-78.0),降至每年97000例(95%CI 58000-160000)。
  • 加用母体抗病毒预防且覆盖率达90%可使传播减少86.3%(95%CI 78.4-94.6),降至每年24000例(95%CI 14000-39000;占活产的0.06%),并达到WHO消除目标。

关键数值与推荐

  • 2022年垂直传播事件:172000例(95%CI 82000-383000),占活产0.4%。
  • 2001年垂直传播峰值:339000例(95%CI 149000-634000),占全部活产1.2%。
  • 出生剂量疫苗接种覆盖率提高至WHO目标90%:垂直传播减少43.7%(95%CI 11.6-78.0),降至每年97000例(95%CI 58000-160000)。
  • 加用母体抗病毒预防且覆盖率90%:传播减少86.3%(95%CI 78.4-94.6),降至每年24000例(95%CI 14000-39000;占活产0.06%),达到WHO消除目标。

临床怎么用

  • 作者结论指出垂直传播是WHO非洲区域HBV传播的重要贡献因素,亟需扩大乙肝出生剂量疫苗接种和抗病毒预防,以实现垂直传播的消除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More new infections with hepatitis B virus (HBV) occur annually in the WHO African region than in the rest of the world combined. We did a systematic review and meta-analysis to estimate the prevalence of hepatitis B surface antigen (HBsAg) in pregnant women and vertical transmission events in the region. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, Africa Index Medicus, and Africa Journals Online for publications between Jan 1, 1992, and Jan 7, 2024, with no language restrictions. HBsAg prevalence and vertical transmission (HBsAg positivity in children aged 6-12 months) were estimated with the use of binomial mixed models with logit links, stratified by infant vaccination status. We estimated HBsAg prevalence for subregions of Africa and for the WHO African region by weighting by estimated livebirths for each subregion. We estimated transmission events using WHO and UNICEF vaccine coverage data and UN population estimates. FINDINGS: We included 113 studies reporting on HBsAg prevalence from 190 983 pregnant women and 11 studies reporting on vertical transmission. HBsAg prevalence in women receiving antenatal care in the WHO African region (based on 2014-23 data) was 6·2% (95% CI 5·3-7·2). No relationship between risk of bias and HBsAg prevalence was observed. In 2022, an estimated 172 000 vertical transmission events (95% CI 82 000-383 000) occurred (0·4% of livebirths), a fall from a peak of 339 000 (149 000-634 000; 1·2% of all livebirths) in 2001. Increasing birth dose vaccination coverage to the WHO target of 90% could reduce vertical transmission by 43·7% (95% CI 11·6-78·0) to 97 000 events per year (95% CI 58 000-160 000). Adding maternal antiviral prophylaxis with 90% coverage could reduce transmission by 86·3% (95% CI 78·4-94·6) to 24 000 events per year (95% CI 14 000-39 000; 0·06% of livebirths) and achieve WHO elimination targets. INTERPRETATION: Vertical transmission is an important contributor to HBV transmission in the WHO African region. Scaling up of hepatitis B birth dose vaccination and antiviral prophylaxis is urgently needed, which could achieve elimination of vertical transmission. FUNDING: Wellcome Trust.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Riches N, Henrion MYR, MacPherson P, et al. Vertical transmission of hepatitis B virus in the WHO African region: a systematic review and meta-analysis. Lancet Glob Health. 2025. PMID: 40021303. doi:10.1016/S2214-109X(24)00506-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。